^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | nintedanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
Published date:
05/10/2023
Excerpt:
In MKN-45 GAC cell-derived peritoneal dissemination xenografts, animal survival was improved by nintedanib (33%), docetaxel (100%) and irinotecan (181%)...%) and irinotecan (332%)... In KATO-III GAC cell-derived xenografts carrying FGFR2 gene amplification, nintedanib extended survival by 209%...In MKN-45 subcutaneous xenografts, nintedanib, epirubicin, docetaxel and irinotecan reduced tumor growth (range: 68-87%)...Nintedanib showed notable antitumor efficacy and significantly improved taxane or irinotecan chemotherapy responses. These findings indicate that nintedanib, alone and in combination with a taxane or irinotecan, has the potential for improving clinical GAC therapy.
Secondary therapy:
docetaxel; irinotecan
DOI:
10.3389/fonc.2023.1145999
Source:
Title:
Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
Published date:
05/10/2023
Excerpt:
In MKN-45 GAC cell-derived peritoneal dissemination xenografts, animal survival was improved by nintedanib (33%), docetaxel (100%) and irinotecan (181%)...%) and irinotecan (332%)...In KATO-III GAC cell-derived xenografts carrying FGFR2 gene amplification, nintedanib extended survival by 209%...In MKN-45 subcutaneous xenografts, nintedanib, epirubicin, docetaxel and irinotecan reduced tumor growth (range: 68-87%)...Nintedanib showed notable antitumor efficacy and significantly improved taxane or irinotecan chemotherapy responses. These findings indicate that nintedanib, alone and in combination with a taxane or irinotecan, has the potential for improving clinical GAC therapy.
DOI:
10.3389/fonc.2023.1145999
Source:
Title:
1043 - Enhancing cytotoxic chemotherapy effects by nintedanib in gastric cancer preclinical models
Published date:
03/10/2021
Excerpt:
In KATO-III cell-derived xenografts carrying FGFR2 gene amplification, nintedanib monotherapy extended survival much more (209%). Docetaxel and irinotecan effects were again further enhanced by nintedanib.
Secondary therapy:
docetaxel
Source:
Title:
1043 - Enhancing cytotoxic chemotherapy effects by nintedanib in gastric cancer preclinical models
Published date:
03/10/2021
Excerpt:
In KATO-III cell-derived xenografts carrying FGFR2 gene amplification, nintedanib monotherapy extended survival much more (209%). Docetaxel and irinotecan effects were again further enhanced by nintedanib.
Source:
Title:
1043 - Enhancing cytotoxic chemotherapy effects by nintedanib in gastric cancer preclinical models
Published date:
03/10/2021
Excerpt:
In KATO-III cell-derived xenografts carrying FGFR2 gene amplification, nintedanib monotherapy extended survival much more (209%). Docetaxel and irinotecan effects were again further enhanced by nintedanib.
